Grace Therapeutics Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Selling, General & Admin	7.63	7.17	6.68	8.28	9.78	6.66
Research & Development	3.62	9.51	4.68	9.97	5.56	4.17
Other Operating Expenses	-	-	1.49	33.91	0.25	5.7
Total Operating Expenses	11.25	16.68	12.85	52.16	15.59	16.54
Operating Income	-11.25	-16.68	-12.85	-52.16	-15.59	-16.42
Other Non-Operating Income (Expense)	4.25	3.91	-1.83	0.18	-	-3.26
Total Non-Operating Income (Expense)	4.25	3.91	-1.83	0.18	-	-3.26
Pretax Income	-7	-12.77	-14.69	-51.97	-15.59	-19.68
Provision for Income Taxes	-1.02	-3.2	-1.83	-9.54	-0.65	-
Net Income	-5.98	-9.57	-12.85	-42.43	-9.82	-19.68
Net Income to Common	-5.98	-9.57	-12.85	-42.43	-9.82	-19.68
Shares Outstanding (Basic)	16	12	10	7	6	2
Shares Outstanding (Diluted)	16	12	10	7	6	2
Shares Change (YoY)	37.81%	26.85%	28.16%	21.09%	148.46%	40.25%
EPS (Basic)	-0.31	-0.79	-1.35	-5.71	-1.62	-7.98
EPS (Diluted)	-0.31	-0.79	-1.35	-5.71	-1.62	-7.98
Shares Outstanding	15.47	13.72	9.4	7.44	7.38	3.74
Free Cash Flow	-10.13	-14.9	-12.36	-15.93	-17.23	-14.39
Free Cash Flow Per Share	-0.65	-1.23	-1.30	-2.14	-2.81	-5.82
EBITDA	-11.24	-16.67	-12.84	-52.03	-15.59	-15.5
EBIT	-11.25	-16.68	-12.85	-52.16	-15.59	-16.42
Effective Tax Rate	14.55%	25.06%	12.48%	18.36%	4.16%	0.00%

Updated Feb 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q